Tilman’s Post

🌟 Welcome to Day 1 of ARCS Australia Annual Conference 2024! 🌟 We are excited to announce that Opyl (ASX: OPL) Minh-Thu C., our Business Development Manager, and Bernice Averion, our Head of Marketing and Communications, are representing TrialKey at the ARCS Annual Conference in Sydney. Join us at booth M37 at the International Convention Centre Sydney (ICC Sydney), Darling Harbour, from 12-14 June 2024. The theme this year is "The Future Of Medicine: The Confluence of Devices, Drugs, and Data," focusing on the paradigm shift towards a more interconnected, personalized, and data-driven healthcare approach. This integrated method has the potential to revolutionize how diseases are prevented, diagnosed, and treated, ultimately leading to better patient outcomes and more efficient healthcare systems. #ARCS2024 #HealthcareInnovation #ClinicalTrials #AI #Opyl #TrialKey #Pharmaceuticals #DataDrivenHealthcare #PersonalizedMedicine #ICCSydney

Nanopharm Ltd, an Aptar Pharma Company were delighted to attend SMI.London last month. Key insights and thought provoking messages from the event highlighted the following comparisons between Soft Mist Inhalers (SMIs) and nebulisers as pulmonary delivery systems during development: 🔷 Drug Delivery: SMIs were shown to deliver more drug product than other pulmonary systems 🔷 Performance: SMIs can perform on par with nebulisers and do not seem to damage molecules e.g. due to excessive shear including biologics 🔷 Breathing Profiles: SMIs utilize bolus breathing, with the aim of delivering the drug to the deep lung 🔷 Environmental Impact: SMIs can demonstrate a lower carbon footprint compared to other pulmonary systems over the life cycle of the device.   These findings underscore the potential of SMIs to enhance drug delivery efficiency and sustainability in respiratory treatments. Talk to Nanopharm at info@nanopharm.co.uk to discuss your OINDP development and support. #SMILondon #DrugDelivery #RespiratoryHealth #MedicalInnovation #InhalationScience

Many thanks to the BEAM Alliance for inviting us to join their webinar series! In today’s session, the Swiss Round Table on Antibiotics made the case for why we need both pull and push incentives to bring new antimicrobial technologies to patients. The speakers, Rudolf Blankart, Chantal Morel, and Barbara Polek, discussed topics such as: - The antibiotic challenge: Why is the #antibiotics market far less attractive than the markets for other #pharmaceuticals? -  "Business as usual" is not an option: If we don’t find a solution to solve the major #publichealth challenge posed by #antimicrobialresistance, the costs of non-action will conceivably be enormous. - Implementation of pull incentives is gaining momentum: England and Sweden have been conducting pilot projects to test revenue guarantee models; other countries are planning to do so. In our White Paper "Effective antibiotics for the Swiss health care system: today and in the future" we suggest how a pilot project could be implemented in Switzerland to test a pull incentive-model. You will find the publication on our website: https://lnkd.in/eYVvPy_T #AMR, #globalhealth, #silentpandemic

📣 Attending CPHI Milan? Meet me at CPHI in beautiful Milano (just 2 hours south by SBB train, from our ten23 health Visp location)! ❓ Got particles? ❓ Need a High Concentration formulation ? ❓ Unclear how to transition your IV product to a SC product, using Prefilled Syringe and Autoinjector, or Cartridge and Large-Volume Device? ❓ Having challenges in developing or manufacturing Intravitreal (IVT) Products? 🤝 Looking forward to discuss challenges and solutions for Pharmaceutical Medicines, and how ten23 health can support you, in developing, manufacturing and testing your sterile drug products. And, if you want to join the dialogue on specific topics, come join me at CPHI Milan for… ✨ 💬 A Panel discussion on “Collaborative Innovation – Advancing Quality & Efficiency for Ready-To-Use Vials” (October 8, Hall 20, 20C33), led by the wonderful Georg Roessling ✨ 💬 The Session on “Leading with Diversity: the CEO journey”, discussing diversity, equity & inclusion (October 10, Hall 6, 6A28). 💉 Visit my ten23 health colleagues Teun van der Heide Dr. Nicolas Brandes Adithya Balasubramanian Carole Delauney (she/her) and myself at our Booth #18G6. 📣 And if you are available for a short detour after or during CPHI to our Site in #Visp, #Valais….let´s schedule doing that and enjoy a fabulous Raclette or Fondue 😊 https://lnkd.in/efZ-4u3t #ten23 #ten23health #CDMO #sterile #product #development #manufacturing #testing #Basel #Visp #Valais #RTU #primarypackaging #CPHI #CPHIMilan #AtTheHeartOfPharma #pharma #biopharma #diversity #equity #inclusion

Thanks to Skylar Jeremias at the Center for Biosimilars, my article again made the top five this week. Please read it. https://lnkd.in/gQGDxpP6

➡ Move Beyond Features and Discover the "So What" Benefits! Elevate your brand by uncovering the deeper "so what" benefits that differentiate you from the competition. Join our webinar on July 25th to learn how to go beyond basic features and truly connect with your audience. 🗓️ Date: July 25th, 2024 🕛 Time: 12:00 pm EST Register Now: https://lnkd.in/gBkhuziR #webinar #pharma #pharmamarketing #brand #brandstrategy #HCP #ZoomRx #biopharmawebinar #pharmastrategy #Lifescience #patients

🎤📋👥𝗜𝗻𝗯𝗲𝗲𝗼'𝘀 𝗽𝗿𝗲𝘀𝗲𝗻𝗰𝗲 𝗮𝘁 𝗜𝗦𝗣𝗢𝗥 𝟮𝟬𝟮𝟰!🎤📋👥 In case you did not get a chance to stop by our poster or missed our podium presentation at ISPOR, here is a summary of activities we participated at ISPOR 2024: Our Inbeeo experts were excited to present and discuss some key topics with attendees during the podium and poster presentations, including: 1.   Assessing the Impact of Access Policies on Biosimilar Pricing: A Comparative Study of Five Major European Markets 2.   Reimbursement Incentives for Antibiotics in Eleven European Countries: A Comparative Analysis ✨ Stay tuned for upcoming posts, where we will dive deeper into each of these topics! ✨ Feel free to reach out if you’d like to continue the conversation or have any questions. Thanks to everyone who joined us—we look forward to connecting with you again! #ISPOR #MarketAccess #Inbeeo #HealthEconomics #HTA #Pharma

As the 10th anniversary of the first biosimilar approval in the United States approaches, understanding how the biosimilar environment has changed since 2015 will be key for providers, patients, payer organizations, and policymakers hoping to realize the benefits of biosimilars. My colleagues (Hanaa Siddiqi, Ben Diner, and Melissa Caplen) and I recently authored a white paper discussing the following on biosimilars in the United States: -Biosimilar landscape -Evolution of the barriers -Formulary coverage and uptake -How the #InflationReductionAct may impact the market

Medicine cures diseases, but doctors cure patients. This National Doctors' Day, ZIM Labs celebrates the heroes, whose wings of compassion and stethoscopes of expertise uplift spirits and mend hearts. Join us in expressing gratitude to doctors everywhere for their extraordinary contributions to healthcare. Visit https://www.zimlab.in/ to know more. #Doctor #NationalDoctorsDay #DoctorDay #ZIMLabs #Pharmaceuticals #InnovationInPharmaceuticals #ResearchAndDevelopment #PharmaIndustry #HealthScience #PharmaceuticalSolutions #PharmaceuticalResearch #ClinicalTrial

Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy.1  DMI is a common, irreversible complication of diabetic retino... https://buff.ly/4abidBG Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy.1  DMI is a common, irreversible complication of diabetic retino... #pharma #biotech #lifesciences #clinicalresearch #news #pharmiweb